Unity Biotechnology Long Term Debt

Unity Biotechnology (UBX) currently reports a long-term debt of $19M as of March 2025. That compares with $23M in the prior-year period — down 17.4% year over year. Use the charts on this page to explore Unity Biotechnology's long-term debt history and peer comparisons.

Unity Biotechnology's long-term debt decreased from $23M to $19M — a 17.4% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Unity Biotechnology reported $19M in long-term debt as of March 2025. That compares with $23M in the prior-year period — down 17.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $19M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Unity Biotechnology, and consider following UBX for alerts when major investors trade the stock.

Unity Biotechnology is classified in the Healthcare sector. On long-term debt, it currently shows $19M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing UBX with unrelated industries.